Incannex Healthcare Inc. has announced an enhanced clinical development strategy for its lead drug candidate IHL-42X, following positive Phase 2 trial results. The FDA has granted Fast Track Designation, allowing for expedited development and regulatory interactions.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.